Compare RGR & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGR | TRDA |
|---|---|---|
| Founded | 1949 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.9M | 481.6M |
| IPO Year | 1994 | 2021 |
| Metric | RGR | TRDA |
|---|---|---|
| Price | $38.93 | $12.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $43.00 | $20.00 |
| AVG Volume (30 Days) | 135.6K | ★ 185.5K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $546,057,000.00 | $25,421,000.00 |
| Revenue This Year | $1.05 | $39.97 |
| Revenue Next Year | N/A | $53.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.94 | N/A |
| 52 Week Low | $28.33 | $4.93 |
| 52 Week High | $48.21 | $13.99 |
| Indicator | RGR | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 53.83 |
| Support Level | $35.41 | $9.78 |
| Resistance Level | $47.86 | $12.56 |
| Average True Range (ATR) | 1.35 | 0.94 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 72.24 | 49.66 |
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.